Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Calcitonin Clear all
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

NCT00525798
View directory record Official record
Conditions
Osteoporosis
Interventions
SMC021 Oral calcitonin, SMC021 Placebo
Drug
Lead sponsor
Nordic Bioscience A/S
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
4,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Gainesville, Georgia • Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients

NCT03898856
View directory record Official record
Conditions
Chronic Diarrhea of Unknown Origin
Interventions
Crofelemer, Diagnostic tests for cause of chronic diarrhea
Drug · Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 23, 2026, 10:18 AM EDT
Completed No phase listed Observational

Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia

NCT00914550
View directory record Official record
Conditions
Pneumonia, Radiographic Lung Infiltrates
Interventions
Procalcitonin level, caregiver informed
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

Phase II Study of Calcitonin for Tumoral Calcinosis

NCT00004358
View directory record Official record
Conditions
Calcinosis
Interventions
calcitonin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 10:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

NCT05895500
View directory record Official record
Conditions
Dry Eye, Asthenopia
Interventions
Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral
Drug
Lead sponsor
Nvision Laser Eye Centers
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 23, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional Results available

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Poorly Differentiated Thyroid Gland Carcinoma
Interventions
Lenvatinib, Sorafenib, Cabozantinib, Vandetanib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

NCT06004388
View directory record Official record
Conditions
Migraine, Episodic Migraine, Headache, Headache, Migraine
Interventions
Click Digital Therapeutic
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Calcitonin Gene-related Peptide Levels in Chronic Migraine

NCT01071096
View directory record Official record
Conditions
Chronic Migraine
Interventions
OnabotulinumtoxinA, Saline
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Springfield, Missouri • Plainview, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 23, 2026, 10:18 AM EDT
Not yet recruiting Not applicable Interventional

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

NCT07612293
View directory record Official record
Conditions
Thyroid Gland Medullary Carcinoma
Interventions
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan, Neck Dissection, Surveillance, Thyroid Lobectomy, Thyroidectomy, Ultrasound Imaging
Procedure · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 23, 2026, 10:18 AM EDT
Completed No phase listed Observational

Pro-Calcitonin Levels Following Pediatric Cardiac Surgery

NCT00284570
View directory record Official record
Conditions
Congenital Heart Disease, Sepsis, Infection
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 5 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Hypothyroidism Treated With Calcitonin

NCT03342001
View directory record Official record
Conditions
Hypothyroidism
Interventions
Calcitonin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

Repeat Dosing of Psilocybin in Migraine Headache

NCT04218539
View directory record Official record
Conditions
Migraine Headache
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 23, 2026, 10:18 AM EDT
Terminated Phase 4 Interventional Results available

Real World Effectiveness of Eptinezumab in Participants With Migraine

NCT05284019
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 23, 2026, 10:18 AM EDT
Completed Not applicable Interventional Results available

Calcitonin for Treating X-linked Hypophosphatemia

NCT01652573
View directory record Official record
Conditions
Hypophosphatemic Rickets, X Linked Dominant
Interventions
nasal salmon calcitonin, Saline Nasal Spray Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 23, 2026, 10:18 AM EDT
Recruiting No phase listed Observational

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750
View directory record Official record
Conditions
Migraine, Episodic Migraine, Chronic Migraine, Headache
Interventions
CGRP antibody or gepant
Drug
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 23, 2026, 10:18 AM EDT